TY  - JOUR
AU  - Wardlaw, Joanna M
AU  - Chabriat, Hugues
AU  - de Leeuw, Frank-Erik
AU  - Debette, Stéphanie
AU  - Dichgans, Martin
AU  - Doubal, Fergus
AU  - Jokinen, Hanna
AU  - Katsanos, Aristeidis H
AU  - Ornello, Raffaele
AU  - Pantoni, Leonardo
AU  - Pasi, Marco
AU  - Pavlović, Aleksandra
AU  - Rudilosso, Salvatore
AU  - Schmidt, Reinhold
AU  - Staals, Julie
AU  - Taylor-Rowan, Martin
AU  - Hussain, Salman
AU  - Lindgren, Arne G
PY  - 2024
UR  - https://doi.org/10.1177/23969873231219416
UR  - internal-pdf://2338/Wardlaw et al. - 2024 - European stroke organisation (ESO) guideline on ce.pdf
UR  - http://rfasper.fasper.bg.ac.rs/handle/123456789/5408
AB  - A quarter of ischaemic strokes are lacunar subtype, typically neurologically mild, usually resulting from intrinsic cerebral small vessel pathology, with risk factor profiles and outcome rates differing from other stroke subtypes. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations to assist with clinical decisions about management of lacunar ischaemic stroke to prevent adverse clinical outcomes. The guideline was developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We addressed acute treatment (including progressive lacunar stroke) and secondary prevention in lacunar ischaemic stroke, and prioritised the interventions of thrombolysis, antiplatelet drugs, blood pressure lowering, lipid lowering, lifestyle, and other interventions and their potential effects on the clinical outcomes recurrent stroke, dependency, major adverse cardiovascular events, death, cognitive decline, mobility, gait, or mood disorders. We systematically reviewed the literature, assessed the evidence and where feasible formulated evidence-based recommendations, and expert concensus statements. We found little direct evidence, mostly of low quality. We recommend that patients with suspected acute lacunar ischaemic stroke receive intravenous alteplase, antiplatelet drugs and avoid blood pressure lowering according to current acute ischaemic stroke guidelines. For secondary prevention, we recommend single antiplatelet treatment long-term, blood pressure control, and lipid lowering according to current guidelines. We recommend smoking cessation, regular exercise, other healthy lifestyle modifications, and avoid obesity for general health benefits. We cannot make any recommendation concerning progressive stroke or other drugs. Large randomised controlled trials with clinically important endpoints, including cognitive endpoints, are a priority for lacunar ischaemic stroke.
PB  - Sage
T2  - European Stroke Journal
T2  - European Stroke Journal
T1  - European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke
SP  - 23969873231219416
DO  - 10.1177/23969873231219416
ER  - 

@article{
author = "Wardlaw, Joanna M and Chabriat, Hugues and de Leeuw, Frank-Erik and Debette, Stéphanie and Dichgans, Martin and Doubal, Fergus and Jokinen, Hanna and Katsanos, Aristeidis H and Ornello, Raffaele and Pantoni, Leonardo and Pasi, Marco and Pavlović, Aleksandra and Rudilosso, Salvatore and Schmidt, Reinhold and Staals, Julie and Taylor-Rowan, Martin and Hussain, Salman and Lindgren, Arne G",
year = "2024",
abstract = "A quarter of ischaemic strokes are lacunar subtype, typically neurologically mild, usually resulting from intrinsic cerebral small vessel pathology, with risk factor profiles and outcome rates differing from other stroke subtypes. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations to assist with clinical decisions about management of lacunar ischaemic stroke to prevent adverse clinical outcomes. The guideline was developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We addressed acute treatment (including progressive lacunar stroke) and secondary prevention in lacunar ischaemic stroke, and prioritised the interventions of thrombolysis, antiplatelet drugs, blood pressure lowering, lipid lowering, lifestyle, and other interventions and their potential effects on the clinical outcomes recurrent stroke, dependency, major adverse cardiovascular events, death, cognitive decline, mobility, gait, or mood disorders. We systematically reviewed the literature, assessed the evidence and where feasible formulated evidence-based recommendations, and expert concensus statements. We found little direct evidence, mostly of low quality. We recommend that patients with suspected acute lacunar ischaemic stroke receive intravenous alteplase, antiplatelet drugs and avoid blood pressure lowering according to current acute ischaemic stroke guidelines. For secondary prevention, we recommend single antiplatelet treatment long-term, blood pressure control, and lipid lowering according to current guidelines. We recommend smoking cessation, regular exercise, other healthy lifestyle modifications, and avoid obesity for general health benefits. We cannot make any recommendation concerning progressive stroke or other drugs. Large randomised controlled trials with clinically important endpoints, including cognitive endpoints, are a priority for lacunar ischaemic stroke.",
publisher = "Sage",
journal = "European Stroke Journal, European Stroke Journal",
title = "European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke",
pages = "23969873231219416",
doi = "10.1177/23969873231219416"
}

Wardlaw, J. M., Chabriat, H., de Leeuw, F., Debette, S., Dichgans, M., Doubal, F., Jokinen, H., Katsanos, A. H., Ornello, R., Pantoni, L., Pasi, M., Pavlović, A., Rudilosso, S., Schmidt, R., Staals, J., Taylor-Rowan, M., Hussain, S.,& Lindgren, A. G.. (2024). European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke. in European Stroke Journal
Sage., 23969873231219416.
https://doi.org/10.1177/23969873231219416

Wardlaw JM, Chabriat H, de Leeuw F, Debette S, Dichgans M, Doubal F, Jokinen H, Katsanos AH, Ornello R, Pantoni L, Pasi M, Pavlović A, Rudilosso S, Schmidt R, Staals J, Taylor-Rowan M, Hussain S, Lindgren AG. European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke. in European Stroke Journal. 2024;:23969873231219416.
doi:10.1177/23969873231219416 .

Wardlaw, Joanna M, Chabriat, Hugues, de Leeuw, Frank-Erik, Debette, Stéphanie, Dichgans, Martin, Doubal, Fergus, Jokinen, Hanna, Katsanos, Aristeidis H, Ornello, Raffaele, Pantoni, Leonardo, Pasi, Marco, Pavlović, Aleksandra, Rudilosso, Salvatore, Schmidt, Reinhold, Staals, Julie, Taylor-Rowan, Martin, Hussain, Salman, Lindgren, Arne G, "European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke" in European Stroke Journal (2024):23969873231219416,
https://doi.org/10.1177/23969873231219416 . .

TY  - JOUR
AU  - Verdelho, Ana
AU  - Biessels, Geert Jan
AU  - Chabriat, Hugues
AU  - Charidimou, Andreas
AU  - Duering, Marco
AU  - Godefroy, Olivier
AU  - Pantoni, Leonardo
AU  - Pavlović, Aleksandra
AU  - Wardlaw, Joanna
PY  - 2021
UR  - http://rfasper.fasper.bg.ac.rs/handle/123456789/1326
AB  - Purpose: Practical suggestions on clinical decisions about vascular disease management in patients with cognitive impairment are proposed. Methods: The document was produced by the Dementia Committee of the European Stroke Organisation (ESO) based on the evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO. Findings: Vascular risk factors and cerebrovascular disease are frequent in patients with cognitive impairment. While acute stroke treatment has evolved substantially in last decades, evidence of management of cerebrovascular pathology beyond stroke in patients with cognitive impairment and dementia is quite limited. Additionally, trials to test some daily-life clinical decisions are likely to be complex, difficult to undertake and take many years to provide sufficient evidence to produce recommendations. This document was conceived to provide some suggestions until data from field trials are available. It was conceived for the use of clinicians from memory clinics or involved specifically in cognitive disorders, addressing practical aspects on diagnostic tools, vascular risk management and suggestions on some therapeutic options. Discussion and conclusions: The authors did not aim to do an exhaustive or systematic review or to cover all current evidence. The document approach in a very practical way frequent issues concerning cerebrovascular disease in patients with known cognitive impairment.
PB  - Sage Publications Ltd, London
T2  - European Stroke Journal
T1  - Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee - A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics
EP  - 119
IS  - 2
SP  - 111
VL  - 6
DO  - 10.1177/2396987321994294
ER  - 

@article{
author = "Verdelho, Ana and Biessels, Geert Jan and Chabriat, Hugues and Charidimou, Andreas and Duering, Marco and Godefroy, Olivier and Pantoni, Leonardo and Pavlović, Aleksandra and Wardlaw, Joanna",
year = "2021",
abstract = "Purpose: Practical suggestions on clinical decisions about vascular disease management in patients with cognitive impairment are proposed. Methods: The document was produced by the Dementia Committee of the European Stroke Organisation (ESO) based on the evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO. Findings: Vascular risk factors and cerebrovascular disease are frequent in patients with cognitive impairment. While acute stroke treatment has evolved substantially in last decades, evidence of management of cerebrovascular pathology beyond stroke in patients with cognitive impairment and dementia is quite limited. Additionally, trials to test some daily-life clinical decisions are likely to be complex, difficult to undertake and take many years to provide sufficient evidence to produce recommendations. This document was conceived to provide some suggestions until data from field trials are available. It was conceived for the use of clinicians from memory clinics or involved specifically in cognitive disorders, addressing practical aspects on diagnostic tools, vascular risk management and suggestions on some therapeutic options. Discussion and conclusions: The authors did not aim to do an exhaustive or systematic review or to cover all current evidence. The document approach in a very practical way frequent issues concerning cerebrovascular disease in patients with known cognitive impairment.",
publisher = "Sage Publications Ltd, London",
journal = "European Stroke Journal",
title = "Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee - A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics",
pages = "119-111",
number = "2",
volume = "6",
doi = "10.1177/2396987321994294"
}

Verdelho, A., Biessels, G. J., Chabriat, H., Charidimou, A., Duering, M., Godefroy, O., Pantoni, L., Pavlović, A.,& Wardlaw, J.. (2021). Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee - A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics. in European Stroke Journal
Sage Publications Ltd, London., 6(2), 111-119.
https://doi.org/10.1177/2396987321994294

Verdelho A, Biessels GJ, Chabriat H, Charidimou A, Duering M, Godefroy O, Pantoni L, Pavlović A, Wardlaw J. Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee - A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics. in European Stroke Journal. 2021;6(2):111-119.
doi:10.1177/2396987321994294 .

Verdelho, Ana, Biessels, Geert Jan, Chabriat, Hugues, Charidimou, Andreas, Duering, Marco, Godefroy, Olivier, Pantoni, Leonardo, Pavlović, Aleksandra, Wardlaw, Joanna, "Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee - A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics" in European Stroke Journal, 6, no. 2 (2021):111-119,
https://doi.org/10.1177/2396987321994294 . .

TY  - JOUR
AU  - Verdelho, Ana
AU  - Wardlaw, Joanna
AU  - Pavlović, Aleksandra
AU  - Pantoni, Leonardo
AU  - Godefroy, Olivier
AU  - Duering, Marco
AU  - Charidimou, Andreas
AU  - Chabriat, Hugues
AU  - Biessels, Geert Jan
PY  - 2021
UR  - http://rfasper.fasper.bg.ac.rs/handle/123456789/1324
AB  - Purpose Many daily-life clinical decisions in patients with cerebrovascular disease and cognitive impairment are complex. Evidence-based information sustaining these decisions is frequently lacking. The aim of this paper is to propose a practical clinical approach to cognitive impairments in patients with known cerebrovascular disease. Methods The document was produced by the Dementia Committee of the European Stroke Organisation (ESO), based on evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO. Findings Many patients with stroke or other cerebrovascular disease have cognitive impairment, but this is often not recognized. With improvement in acute stroke care, and with the ageing of populations, it is expected that more stroke survivors and more patients with cerebrovascular disease will need adequate management of cognitive impairment of vascular etiology. This document was conceived for the use of strokologists and for those clinicians involved in cerebrovascular disease, with specific and practical hints concerning diagnostic tools, cognitive impairment management and decision on some therapeutic options. Discussion and conclusions: It is essential to consider a possible cognitive deterioration in every patient who experiences a stroke. Neuropsychological evaluation should be adapted to the clinical status. Brain imaging is the most informative biomarker concerning prognosis. Treatment should always include adequate secondary prevention.
PB  - Sage Publications Ltd, London
T2  - European Stroke Journal
T1  - Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee
EP  - 17
IS  - 1
SP  - 5
VL  - 6
DO  - 10.1177/23969873211000258
ER  - 

@article{
author = "Verdelho, Ana and Wardlaw, Joanna and Pavlović, Aleksandra and Pantoni, Leonardo and Godefroy, Olivier and Duering, Marco and Charidimou, Andreas and Chabriat, Hugues and Biessels, Geert Jan",
year = "2021",
abstract = "Purpose Many daily-life clinical decisions in patients with cerebrovascular disease and cognitive impairment are complex. Evidence-based information sustaining these decisions is frequently lacking. The aim of this paper is to propose a practical clinical approach to cognitive impairments in patients with known cerebrovascular disease. Methods The document was produced by the Dementia Committee of the European Stroke Organisation (ESO), based on evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO. Findings Many patients with stroke or other cerebrovascular disease have cognitive impairment, but this is often not recognized. With improvement in acute stroke care, and with the ageing of populations, it is expected that more stroke survivors and more patients with cerebrovascular disease will need adequate management of cognitive impairment of vascular etiology. This document was conceived for the use of strokologists and for those clinicians involved in cerebrovascular disease, with specific and practical hints concerning diagnostic tools, cognitive impairment management and decision on some therapeutic options. Discussion and conclusions: It is essential to consider a possible cognitive deterioration in every patient who experiences a stroke. Neuropsychological evaluation should be adapted to the clinical status. Brain imaging is the most informative biomarker concerning prognosis. Treatment should always include adequate secondary prevention.",
publisher = "Sage Publications Ltd, London",
journal = "European Stroke Journal",
title = "Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee",
pages = "17-5",
number = "1",
volume = "6",
doi = "10.1177/23969873211000258"
}

Verdelho, A., Wardlaw, J., Pavlović, A., Pantoni, L., Godefroy, O., Duering, M., Charidimou, A., Chabriat, H.,& Biessels, G. J.. (2021). Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee. in European Stroke Journal
Sage Publications Ltd, London., 6(1), 5-17.
https://doi.org/10.1177/23969873211000258

Verdelho A, Wardlaw J, Pavlović A, Pantoni L, Godefroy O, Duering M, Charidimou A, Chabriat H, Biessels GJ. Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee. in European Stroke Journal. 2021;6(1):5-17.
doi:10.1177/23969873211000258 .

Verdelho, Ana, Wardlaw, Joanna, Pavlović, Aleksandra, Pantoni, Leonardo, Godefroy, Olivier, Duering, Marco, Charidimou, Andreas, Chabriat, Hugues, Biessels, Geert Jan, "Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee" in European Stroke Journal, 6, no. 1 (2021):5-17,
https://doi.org/10.1177/23969873211000258 . .